Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on Moderna to $225 from $185 and keeps a Buy rating on the shares. The analyst trimmed fiscal 2024 revenue estimates and thinks Moderna will now lose money this year given the "planned R&D burn." On the plus side, updates this week were incrementally positive, says the analyst, who lifed the price target to both reflect the positive recent news flow.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRNA:
- Senator Sanders says Moderna COVID vaccine pricing shows ‘unacceptable’ greed
- Moderna (NASDAQ:MRNA) Set to Match Pfizer’s Price for COVID Vaccine
- Moderna considering $110-$130 for COVID shot, similar to Pfizer’s, WSJ says
- Moderna expects minimum Covid-19 vaccine sales of $5B in 2023
- Moderna announces updates on mRNA pipeline